These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27858162)

  • 1. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
    Tokas T; Avgeris M; Alamanis C; Scorilas A; Stravodimos KG; Constantinides CA
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):521-532. PubMed ID: 27858162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
    Gueugnon F; Barascu A; Mavridis K; Petit-Courty A; Marchand-Adam S; Gissot V; Scorilas A; Guyetant S; Courty Y
    Tumour Biol; 2015 Jul; 36(7):4979-86. PubMed ID: 25677900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors.
    Foutadakis S; Avgeris M; Tokas T; Stravodimos K; Scorilas A
    Urol Oncol; 2014 Jan; 32(1):39.e29-36. PubMed ID: 23790536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.
    Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A
    Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
    Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
    White NM; Mathews M; Yousef GM; Prizada A; Popadiuk C; Doré JJ
    Br J Cancer; 2009 Oct; 101(7):1107-13. PubMed ID: 19707197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer.
    Chang A; Yousef GM; Scorilas A; Grass L; Sismondi P; Ponzone R; Diamandis EP
    Br J Cancer; 2002 May; 86(9):1457-64. PubMed ID: 11986781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma.
    Nohara K; Yamada K; Yamada L; Hagiwara T; Igari T; Yokoi C; Soma D; Yamashita S; Dohi T; Kawamura YI
    Gen Thorac Cardiovasc Surg; 2018 Jun; 66(6):351-357. PubMed ID: 29582368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.
    Zhang S; Li J; Zhou G; Mu D; Yan J; Xing J; Yao Z; Sheng H; Li D; Lv C; Sun B; Hong Q; Guo H
    Tumour Biol; 2016 Apr; 37(4):5165-70. PubMed ID: 26547586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
    Michaelidou K; Ardavanis A; Scorilas A
    Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer.
    Zhang S; Zhang G; Guo H
    Tumour Biol; 2017 Jun; 39(6):1010428317703822. PubMed ID: 28621231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
    Foteinou E; Kontos CK; Giotakis AI; Scorilas A
    Biol Chem; 2014 Sep; 395(9):1051-62. PubMed ID: 24854539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
    Kontos CK; Adamopoulos PG; Papageorgiou SG; Pappa V; Scorilas A
    Clin Chem Lab Med; 2016 Feb; 54(2):315-24. PubMed ID: 26351937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancer.
    Gruba N; Rachubik P; Piwkowska A; Lesner A
    Biomarkers; 2021 Dec; 26(8):770-779. PubMed ID: 34704886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.